Nobel laureate and immunologist Tasuku Honjo on Tuesday called for a better environment in Japan for conducting research in the life sciences, saying more efforts are needed by both the private and public sectors in enabling researchers to come up with medical cures for illnesses such as cancer. The Kyoto University professor, who was awarded this year's Nobel Prize in medicine for his studies on cancer therapy that focus on controlling the immune system, told a meeting of ruling lawmakers at the Liberal Democratic Party headquarters in Tokyo about difficulties in the process that led to the development of the immunotherapeutic drug Opdivo. He spoke of his partnership with a Japanese pharmaceutical firm that didn't always work, his cooperation with a U.S. company that led to clinical trials for the drug and his recollection that the favorable results of the tests that came out in 2012 were not covered by the Japanese media. "Researchers around the world were surprised by the results because at the time people didn't think immunotherapy was effective in treating cancer," Honjo said. "Most of the patients who took part in the clinical trials were terminal cancer patients and the drug was effective for 20 to 30 percent of those patients. In addition, the effect continued even after administering of the medicine was stopped after half a year," he said.
Oct-23-2018, 12:32:06 GMT